Savior Lifetec Asset Resilience Ratio
Savior Lifetec asset resilience ratio. Savior Lifetec (4167) has an Asset Resilience Ratio of 18.86% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See how many days can Savior Lifetec fund operations to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Savior Lifetec (2017–2025)
Asset resilience ratio of Savior Lifetec from 2017 to 2025. This chart shows how Savior Lifetec's Asset Resilience Ratio has changed over time. Read 4167 total debt and obligations for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Savior Lifetec's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see 4167 total assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 0% |
| Short-term Investments | NT$789.00 Million | 18.86% |
| Total Liquid Assets | NT$789.00 Million | 18.86% |
Asset Resilience Insights
- Good Liquidity Position: Savior Lifetec maintains a healthy 18.86% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
Savior Lifetec Industry Peers by Asset Resilience Ratio
Compare Savior Lifetec's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL |
Biotechnology | 62.31% |
|
Verona Pharma plc
F:I9SA |
Biotechnology | 0.00% |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA |
Biotechnology | 33.37% |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252 |
Biotechnology | 2.03% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
Bavarian Nordic
CO:BAVA |
Biotechnology | 10.83% |
|
Hebei Changshan Biochem Pharma
SHE:300255 |
Biotechnology | -0.03% |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287 |
Biotechnology | 37.31% |
Savior Lifetec Asset Resilience Ratio by Year (2017–2025)
Savior Lifetec asset resilience ratio by year from 2017 to 2025. The table below shows the annual Asset Resilience Ratio data for Savior Lifetec.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 18.86% | NT$789.00 Million ≈ $24.86 Million |
NT$4.18 Billion ≈ $131.82 Million |
+1.47pp |
| 2024-12-31 | 17.39% | NT$761.06 Million ≈ $23.98 Million |
NT$4.38 Billion ≈ $137.87 Million |
+10.74pp |
| 2023-12-31 | 6.65% | NT$254.27 Million ≈ $8.01 Million |
NT$3.82 Billion ≈ $120.44 Million |
-6.14pp |
| 2022-12-31 | 12.79% | NT$563.76 Million ≈ $17.76 Million |
NT$4.41 Billion ≈ $138.90 Million |
+12.44pp |
| 2021-12-31 | 0.35% | NT$15.71 Million ≈ $495.01K |
NT$4.54 Billion ≈ $142.99 Million |
-2.13pp |
| 2020-12-31 | 2.47% | NT$119.65 Million ≈ $3.77 Million |
NT$4.84 Billion ≈ $152.38 Million |
+1.88pp |
| 2019-12-31 | 0.60% | NT$24.13 Million ≈ $760.13K |
NT$4.03 Billion ≈ $127.07 Million |
-1.60pp |
| 2018-12-31 | 2.19% | NT$77.42 Million ≈ $2.44 Million |
NT$3.53 Billion ≈ $111.20 Million |
+2.18pp |
| 2017-12-31 | 0.01% | NT$420.00K ≈ $13.23K |
NT$3.95 Billion ≈ $124.37 Million |
-- |
About Savior Lifetec
Savior Lifetec Corporation, a specialty injectable company, develops, produces, and supplies sterile active pharmaceutical ingredients and finished dosage formulations. The company provides various carbapenem generic drugs and injections, such as paliperidone palmitate, cetrorelix and ganirelix acetate, plecanatide, prucalopride succinate, and brinzolamide. It offers imipenem and cilastatin, mero… Read more